STING1 and cancer: In this field, recent evidence demonstrates that STINGlow (knock down) compared to STINGhigh cancer cells are slightly more susceptible to lysis and still succumb in an immunogenic way following treatment with T-VEC [27,28], but the complete loss of STING that often occurs in cancer cells needs to be assessed.